https://www.selleckchem.com/pr....oducts/lixisenatide.
Teprotumumab is an insulin-like growth factor-1 receptor (IGF-1R) inhibitor demonstrated to improve proptosis in patients with active thyroid eye disease. Most adverse events reported are mild or moderate in severity; however, inflammatory bowel disease (IBD) is a serious adverse event that can develop as a result of treatment.Use of organophosphorus flame retardants (OPFRs) in consumer materials have led to widespread human exposure.Research is needed to examine the health effects attributable to the general population's exposure
Like
Comment
Share
